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BACKGROUND: Oesophageal squamous cell carcinoma (SCC) causes the highest number of cancer deaths in some regions of
Northern China. Previously, we narrowed down a critical region at 9q33-34, identified to be associated with tumour-suppressive
function of deleted in oesophageal cancer 1 (DEC1) in oesophageal SCC.
METHODS: We generated DEC1 antibody and constructed tissue microarrays (TMAs) utilising tissue specimens from Henan,
a high-risk region for oesophageal SCC, to investigate the importance of DEC1 expression in this cancer.
RESULTS: Tissue microarray immunohistochemical staining reveals significant loss of DEC1 from hyperplasia, to tumour, and to lymph
node metastasis. In addition, the loss of DEC1 in tumour is age-dependent. Interestingly, there is significant abrogation of DEC1
expression in patients with a family history of oesophageal SCC. Deleted in oesophageal cancer 1 localises to both the cytoplasm and
nucleus. The vesicular pattern of DEC1 in the cytoplasm appears to localise at the Golgi and Golgi–endoplasmic reticulum
intermediate compartment.
CONCLUSION: This is the first TMA study to suggest a clinical association of DEC1 in lymph node metastatic oesophageal SCC, early
onset oesophageal SCC and familial oesophageal SCC development. Subcellular localisation of DEC1 and its expression in
oesophageal SCC tissues provide important insight for further deciphering the molecular mechanism of DEC1 in oesophageal SCC
development.
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Oesophageal carcinoma occurs with an especially high frequency
in certain regions of Northern China, including the high-risk
region of Henan (Li, 1982). Allelic losses on human chromosomes
hallmark the presence of tumour-suppressor genes involved in
cancer development. Frequent loss of heterozygosity (LOH) on
chromosome 9 is reported in squamous cell carcinoma (SCC) of
the lung and of the head and neck (Tsuchiya et al, 1992). In
oesophageal SCC, this chromosome 9 loss is also commonly
observed (Ko et al, 2001). Previously, we identified a critical region
at 9q33-34 in oesophageal SCC and identified the importance of
deleted in oesophageal cancer 1 (DEC1), which suppresses
anchorage-independent growth in vitro and tumourigenesis
in vivo (Nishiwaki et al, 2000; Yang et al, 2005). Reverse
transcriptase–PCR analysis shows its frequent downregulation in
an oesophageal SCC cell line panel and primary tumours,
indicating that DEC1 may serve as an early detection biomarker
for oesophageal cancer patients (Leung et al, 2008). Despite the
tumour-suppressive role of DEC1, there are as yet no studies
reported regarding either the role of the protein or its clinical
relevance in oesophageal SCC development. A polyclonal antibody
was generated against DEC1 and used to analyse a tissue
microarray (TMA) constructed with tissues from the oesophageal
SCC high-risk region of Henan, China. Immunohistochemical
(IHC) staining was used to study the association of DEC1
expression according to status of cancer progression, age, and
association with familial oesophageal cancer. Finally, to better
understand the molecular mechanism for DEC1 function, we
examined its subcellular protein cytolocalisation.
MATERIALS AND METHODS
Cell lines, culture conditions, and clinical specimens
The pcDNA 3.1(þ)/DEC1 transfectants and pcDNA3.1(þ) vector-
alone control were cultured in growth medium containing
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s400mgml
–1 G418 (CalBiochem, San Diego, CA, USA), as
previously described (Leung et al, 2008). The SLMT-1 cell line
was established from a Hong Kong Chinese oesophageal SCC
patient (Tang et al, 2001). An immortalised normal oesophageal
epithelial cell line (NE1) was cultured in keratinocyte serum-free
medium (Invitrogen, Carlsbad, CA, USA), as previously described
(Zhang et al, 2006). Oesophageal SCC patient tissues were collected
from the Yaocun Esophageal Cancer Hospital, Linzhou, Henan,
China from 2005 to 2007.
Antibody generation and purification
Bacterial His-tag and GST-tag protein purification systems were
used to purify the DEC1 protein. The DEC1 210bp cDNA fragment
was subcloned from pCR3.1-DEC1 into pGEX-4T-1 (Amersham
Pharmacia Biotech, Uppsala, Sweden) at EcoRI and SalI restriction
sites and into pET28a (Novagen, Madison, WI, USA) at EcoRI and
XhoI sites. Ni-NTA agarose (Qiagen, Hilden, Germany) was used to
purify His-tagged DEC1 protein according to the manufacturer’s
protocol. Purified proteins were dialysed and then emulsified in
adjuvant (Sigma-Aldrich, St Louis, MO, USA). Subsequently, it was
used to immunise New Zealand 2-month-old white rabbits by
subcutaneous methods. Glutathione agarose (GE Healthcare,
London, Canada) was used to purify GST-DEC1 protein according
to the manufacturer’s protocol. The purified GST-tagged DEC1
protein was transferred to a nitrocellulose membrane by SDS–
PAGE. The membrane region containing the GST-tagged DEC1-
sized protein was cut out and incubated with 10ml of the rabbit
serum at 41C overnight. Then 0.1 M glycine buffer (pH 2.0) was
added to elute the antibody. One-tenth volume of Tris-Cl buffer
(pH 8.5) was then added to neutralise the glycine buffer.
Western blot analysis
Preparation of cell lysates, protein electrophoresis, and transfer
were as previously described (Wong et al, 2008). Primary antibody
incubation was performed with DEC1 polyclonal antibody
(1:1000). Ab-1 antibody (1:10000; Calbiochem, Darmstadt,
Germany) was used for detecting alpha-tubulin as a loading
control.
TMA and IHC staining
A TMA was constructed using tissues of 196 oesophageal SCC
patients and 32 non-oesophageal SCC patients from Henan
provided by LD Wang. It comprises normal epithelium from 32
non-oesophageal SCC individuals and 35 matched normal-
appearing oesophageal epithelia, 150 hyperplastic epithelia,
71 carcinoma in situ, 184 primary tumours, and 28 lymph node
metastatic tumours from oesophageal SCC patients. Table 1 shows
the clinical information of these patients. The family history-
positive (FHþ) cases were from individuals having two members
or more with oesophageal SCC within three consecutive genera-
tions. Immunohistochemical staining was performed as previously
described (Yuen et al, 2007) using DEC1 polyclonal antibody
(1:100 dilution) as the primary antibody. The stained sections
were examined by a pathologist (KW Chan), who had no previous
knowledge of the clinico–pathological data of the patients. The
intensity of staining was graded by an arbitrary scale that ranged
from 0 to 3, representing negative (‘0’), weak (‘1’), moderate (‘2’),
and strong (‘3’) staining, respectively. Staining values of 0 and 1
were classified as low expression, while 2 and 3 were classified as
high expression.
Statistical analysis
Associations between clinical pathological information of oeso-
phageal SCC patients and expression of DEC1 were analysed by
w
2 test using SPSS. A P-value below 0.005 was considered
statistically significant after Bonferroni adjustment to control for
type I error from multiple comparisons (Figure 3C). The trend test
for measuring the correlation of DEC1 expression status (high and
low DEC1 staining) with ESCC progression states that include
normal, hyperplasia, carcinoma in situ, tumour, and lymph node
metastasis, was carried out by Gamma test. A P-value of o0.05 was
considered statistically significant.
Subcellular fractionation
Subcellular fractionation was performed as previously described
(Guillemin et al, 2005). Monolayer cultures of NE1 cells on 100mm
diameter culture dishes were harvested by trypsinisation and
resuspended for 5min on ice in 500ml extraction buffer (10mM
HEPES, 10mM NaCl, 1mM KH2PO4,5 m M NaHCO3,5 m M EDTA,
1m M CaCl2, and 0.5mM MgCl2). A volume of 50ml of 2.5 M sucrose
was added to restore isotonic conditions. The lysate was
centrifuged at 6300g for 5min. The supernatant was kept as the
cytoplasmic fraction. The pellet was resuspended in 1ml 500ml
extraction buffer with 2.5 M sucrose and then centrifuged again at
6300g for 5min. The pellet was considered the nuclear fraction.
Anti-lamin A antibody (1:1000, Abcam, Cambridge, UK) was
utilised to detect the nuclear fraction (1:100 dilution).
Immunostaining and colocalisation study
NE1 cells were grown until 80% confluence in 35mm culture
dishes on coverslips. Cells were then fixed in 4% paraformaldehyde
Table 1 Summary of TMA clinico–pathological information for
oesophageal SCC patients
Number
of cases
Valid
percentage (%)
Gender
Male 96 63.6
Female 55 36.4
Total 151
Age
p44 30 19.9
45–69 86 57.0
X70 35 23.2
Total 151
Tissue type
a
Normal 32 6.4
Matched normal
b 35 7.0
Hyperplasia 150 30.0
Carcinoma in situ 71 14.2
Tumour 184 36.8
Lymph node metastasis 28 5.6
Total 500
Stage
I–IIa/b 98 66.7
III–IV 49 33.3
Total 147
Family history
c
Positive 25 50.0
Negative 25 50.0
Total 50
Abbreviations: SCC¼squamous cell carcinoma; TMA¼tissue microarray.
aNot all of
the oesophageal SCC patients had all tissue types available. Only 142 patients had
matched hyperplastic and tumour tissues.
bMatched normal: normal-appearing
oesophageal epithelium from oesophageal SCC patients.
cData of oesophageal SCC
family history are only available in 50 oesophageal SCC patients. In this TMA study,
32 cases of non-oesophageal SCC normal individuals were also included.
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sfor 10min at room temperature and permeabilised with 1% Triton
X-100 in PBS for 10min at room temperature. The procedure for
immunostaining was the same as previously described (Leung
et al, 2008). A nuclear stain, DAPI (Sigma-Aldrich), was applied
at a concentration of 0.1mgml
–1. Finally, the slides were then
mounted with mounting reagent (DAKO, Hamburg, Germany)
and observed by confocal microscopy (LSM 510, Carl Zeiss
MicroImaging GmbH, Jena, Germany). Antibodies against GM130
(BD Biosciences, Labware, MA, USA), ERGIC53 (BD Biosciences),
and Calnexin (Sigma, St Louis, MO, USA) were used to stain Golgi,
Golgi–endoplasmic reticulum (ER) intermediate compartment,
and ER, respectively, at a 1:100 dilution. The images were
captured by confocal microscopy. The scatter plot of the images
was generated and the colocalisation coefficient was measured
by ImageJ (Available at http://rsbweb.nih.gov/ij/; Developed by
National Institutes of Health, Bethesda, MD, USA). Pearson’s
correlation coefficient indicates the degree of colocalisation, with a
value close to 1 meaning perfect colocalisation. Thresholded
Mander’s split colocalisation coefficient provides the proportion of
signals from one channel colocalising with another, with a value of
zero meaning no colocalisation and a value of one corresponding
to perfect colocalisation (Adler and Parmryd, 2010).
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Figure 1 Generation and characterisation of DEC1 antibodies. (A) His-tagged DEC1 proteins were expressed and purified as an antigen to immunise
rabbits. (B) Upper panel: DEC1 antibody specifically recognises recombinant GST–DEC1 fusion proteins, but not GST proteins. Lower panel: the antibody
specifically recognises GFP–DEC1 fusion protein, but not GFP. (C) In immunostaining, DEC1 antibody specifically recognises GFP–DEC1 transiently
transfected HeLa cells. Nonspecific IgG was utilised as a control. BF, bright field. (D) By immunostaining using DEC1 antibodies, higher expression of DEC1 is
detected in stable transfectant (C9) than the vector-alone control (V1).
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sRESULTS
Generation and validation of antibodies
To further our study of DEC1 at the protein level, recombinant
His-tagged DEC1 was purified, emulsified in adjuvant, and then
used to immunise rabbits (Figure 1). The polyclonal DEC1 antibody
can specifically detect GST-tagged DEC1, but not the GST protein
(Figure 1B). The DEC1 antibody specifically recognises the
mammalian-expressed GFP–DEC1 fusion protein, but not GFP
(Figure 1B). By immunostaining using DEC1 antibody, DEC1–GFP
transiently transfected HeLa cells can be detected (Figure 1C).
In addition, ectopic expression of DEC1 can be detected in the
DEC1 stable transfectant (C9) (Figure 1D). All experiments
validated the epitope-affinity and specificity of the DEC1 antibody
for western blot and immunostaining purposes. Thereafter, DEC1
antibodies were utilised to detect DEC1 protein in cell lines and
tissues. Western blot analysis detected expression of both
exogenous and endogenous DEC1 in DEC1 stable transfectants
(SLMT-1 c4 and c9) and the immortalised oesophageal epithelial
cell line, NE1 (Figure 2A). Loss of DEC1 was observed in
DEC1
-Tubulin
-Tubulin
NE1
SLMT-1
SLMT-1 v1
SLMT-1 c4
SLMT-1 c9
77
NN TT N T N T
79 80 84 Normal
DEC1
DEC1 DAPI Merge
DAPI IgG Merge
Figure 2 Endogenous DEC1 detection in primary tissues and cell lines. (A) Endogenous DEC1 expression in the immortalised epithelial cell line, NE1, and
exogenous DEC1 protein in DEC1 stable transfectants (SLMT-1 c4 and c9) were detected by DEC1 antibodies. a-Tubulin serves as control for equal
loading. (B) Downregulation of DEC1 is detected in tumour tissues compared with normal tissues and non-cancer normal individuals. ‘T’, tumour;
‘N’, normal-appearing oesophageal mucosa. (C) Upper panel: in NE1, immunostaining shows DEC1 localised in both nucleus and cytoplasm. A vesicular pattern
was observed at the perinuclear region. Lower panel: immunostaining of NE1 with IgG primary antibody as a control. ‘DAPI’, nuclear stain (scale bar, 20mm).
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Figure 3 Evaluation of clinical significance of DEC1 by TMA. (A) A trend test was performed to correlate DEC1 staining in different levels of cancer
progression. The expression of DEC1 continuously decreased from normal/hyperplasia, to carcinoma in situ, to tumour, and to lymph node metastasis
(Gamma test,  0.44, Po0.001). ‘Normal’ includes oesophageal tissues from non-oesophageal SCC patients and normal-appearing oesophageal epithelium
from oesophageal SCC patients. (B) Representative images in TMA study. High expression of DEC1 in normal and hyperplastic tissues and low expression
of DEC1 in tumour and lymph node metastatic tissues are shown. Normal: tissue from non-cancer normal individuals. (Scale bar, 100mm). (C) Chi-square
analysis was performed to compare the staining of DEC1 between different levels of cancer progression. A P-value o0.005 was regarded as a significant
difference after Bonferroni adjustment to control for type I error and is highlighted and bolded.
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soesophageal SCC tumour tissues compared with corresponding
normal counterparts (Figure 2B). High expression of DEC1 was also
detected in non-cancer normal individuals. Notably, the expression
of DEC1 could also be detected by immunostaining. The DEC1
protein locates to both the cytoplasm and nucleus in NE1 and DEC1
stable transfectants (Figures 1C and 2C).
DEC1 expression is associated with lymph node metastasis,
early onset of oesophageal SCC, and familial oesophageal
SCC development
Tissue microarray analysis was performed using normal epithe-
lium from 32 non-oesophageal SCC patients and tissues from 196
oesophageal SCC patients. First and foremost, the trend test was
performed using Gamma test. A value of  0.404 (P-value o0.001),
indicated a significant trend to show that the cancer progression is
negatively correlated with DEC1 expression. Later cancer stages
were correlated with lower DEC1 expression. The percentage of
high DEC1 staining in hyperplasia is higher than that in normal,
but the difference is not statistically significant. Figure 3A shows
that expression of DEC1 was attenuated from normal/hyperplasia,
to carcinoma in situ, to tumour, and to lymph node metastasis
progression. Thereafter, a w
2 test comparing portion of high/low
DEC1 staining in all levels of cancer progression indicated that
significant difference of DEC1 staining exists between at least two
levels of cancer progression (P-value o0.001). In order to identify
which two levels of cancer progression contained significant
differences of DEC1 staining, w
2 tests were performed to compare
DEC1 staining between different levels of cancer progression
two by two (i.e., normal vs hyperplasia, normal vs tumour, etc.).
Expression of DEC1 was significantly abated in primary tumours
compared with tissues of the normal oesophagus, hyperplasia, and
carcinoma in situ (P-valuep0.001) (Figure 3C). This is consistent
with our previous in vivo and in vitro functional studies identifying
DEC1 as a tumour suppressor of oesophageal SCC (Yang et al,
2005; Leung et al, 2008). Intriguingly, expression of DEC1 was
significantly abrogated in tissues of lymph node metastasis
compared with tissues of normal oesophagus and hyperplasia
(P-valuep0.001) (Figure 3C), suggesting a clinical association of
DEC1 expression with dissemination of oesophageal SCC.
Interestingly, when specimens were analysed according to age
groups, the reduced DEC1 expression levels observed in tumours
compared with hyperplastic tissues is significant only for younger
(30–44 years) and middle-aged (45–69) patients, but not for older
(70–79 years) patients (Table 2). The loss of DEC1 expression in
younger patients is more significant than in middle-aged ones
(P¼0.001 for younger patients and P¼0.006 for middle-aged
patients). These results suggest DEC1 may have a critical role in
early onset of oesophageal SCC development. To determine
whether loss of DEC1 is involved in familial oesophageal SCC
development, we compared DEC1 expression in oesophageal SCC
patients with and without a FH of oesophageal SCC. Significantly
lower expression of DEC1 was observed in both hyperplastic and
tumour tissues of oesophageal cancer FHþ patients, as compared
with oesophageal cancer FH– patients (P¼0.002 for hyperplasia;
P¼0.006 for tumour) (Table 2). Taken together, the TMA analysis
reveals an essential role of DEC1 in not only early onset of
oesophageal SCC malignancies, but also familial oesophageal SCC
development.
Subcellular localisation of DEC1
Identifying the subcellular localisation of a protein provides added
insight which may be useful in deciphering its function. The
protein localisation program PSORT (www.psort.org) predicts that
DEC1 is a cytoplasmic and nuclear protein, while pTARGET
(bioapps.rit.albany.edu/pTARGET/) predicts the localisation of
DEC1 at the Golgi. We confirmed the subcellular location of DEC1
after subcellular fractionation using lysates from NE1. Deleted in
oesophageal cancer 1 was detected in both cytoplasmic and nuclear
fractions (Figure 4A). Consistent with this result, immunostaining
recognised DEC1 in both the cytoplasm and nucleus. A vesicular
pattern of DEC1 staining in the cytoplasm was also detected at the
perinuclear region of interphase cells (Figure 4B). Although no
specific pattern of DEC1 staining was observed in mitosis
(Figure 4B), the vesicular cytoplasmic DEC1 appears to localise
in the Golgi and Golgi–ER intermediate compartment (Figure 4C).
Organelle-specific markers, GM130 for Golgi; Calnexin for ER; and
ERGIC53 for the ER–Golgi intermediate compartment, were
utilised. Immunostaining with the organelle markers GM130 and
ERGIC53 showed a large overlap with DEC1 (Rp¼0.671 for
GM130 and Rp¼0.437 for ERGIC53; Figure 4C). This was not the
case for Calnexin and DEC1 staining and colocalisation is not
obvious (Rp¼0.287; Figure 4C). In summary, DEC1 localises to
the cytoplasm and nucleus and the vesicular pattern of DEC1 in the
cytoplasm appears to localise at the Golgi and ER–Golgi
intermediate compartment.
DISCUSSION
The 5-year survival rates for oesophageal SCC are 37.1% for
primary cancer, 18.5% for regionally spread cancers, and 3.1% for
metastatic cancer (Horner et al, 2009). This highlights the
importance of cancer research in identifying biomarkers for early
Table 2 Evaluation of clinical significance of DEC1 in TMA analysis according to patient age and oesophageal SCC familial history
Abbreviations: DEC1¼deleted in oesophageal cancer 1; FH¼ family history; SCC¼squamous cell carcinoma; TMA¼tissue microarray. The values shown in bold are
statistically significant (P-value o0.05) in chi-square analysis.
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sdiagnosis, to improve survival rates of EC patients. In oesophageal
SCC, LOH at marker D9S910 on 9q was associated with metastasis
(Hu et al, 2000). The 9q31 locus shows an early high frequency of
LOH even in low-grade dysplasia of oesophageal SCC (Mori et al,
1994). In line with these studies, we previously identified a critical
9q33-34 tumour-suppressive region and found that DEC1 is
frequently downregulated at the transcriptional level and func-
tionally involved in suppressing oesophageal SCC tumour forma-
tion in vivo (Nishiwaki et al, 2000; Yang et al, 2005; Leung et al,
2008). Evidence suggests that DEC1 may serve as a good biomarker
for detecting oesophageal SCC. Henan is a high-risk oesophageal
SCC area, where the oesophageal SCC incidence rate is as high as
121 per 100000 population (Xibib et al, 2003). This TMA study
using tissues from Henan patients revealed a trend of increasingly
reduced DEC1 expression with progression from normal, to
hyperplasia, to carcinoma, to tumour, and to lymph node
metastasis. Not only does this study confirm the crucial tumour-
suppressive role of DEC1 in oesophageal SCC, but it also provides
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Figure 4 Identifying the localisation of DEC1. (A) Subcellular fractionation preparations from NE1 lysates show DEC1 in both cytoplasmic and nuclear
fractions. a-Tubulin serves as a control for the cytoplasmic fraction. Laminin-A serves as a control for the nuclear fraction. (B) Localisation pattern of DEC1
was analysed by immunostaining during cell division by DEC1 antibody. DAPI stain for DNA. (Scale bar, 10mm) (C) Colocalisation of DEC1 with different
organelle markers analysed by confocal microscopy. Immunostaining was performed using the immortalised oesophageal epithelial cell line, NE1, with the
ERGIC, GM130, Calnexin, and DEC1 antibodies. Upper panel: immunostaining with ERGIC and DEC1 antibodies. ERGIC is a marker for the ER-Golgi
intermediate compartment. Colocalisation of DEC1 with ERGIC was observed (arrow). Middle panel: immunostaining with GM130 and DEC1 antibodies.
GM130 is a marker for the Golgi. Colocalisation of DEC1 with GM130 was observed (arrow). Lower panel: immunostaining with Calnexin and DEC1
antibodies. Calnexin is an ER marker. No colocalisation of DEC1 with Calnexin was observed. Scale bar, 20mm. Colocalisations (indicated by arrows) are
shown under higher magnification and the region shown in the insert was analysed by ImageJ. The Pearson’s correlation coefficient of DEC1 with GM130,
ERGIC, and Calnexin is 0.671, 0.437, and 0.287, respectively. Thresholded Mander’s split colocalisation coefficient and scatterplot are shown in
Supplementary Figure 1.
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sa novel finding of a clinical association of DEC1 expression with
oesophageal SCC malignancies and metastasis. Interestingly, DEC1
expression is abrogated in tumour tissues from younger oesopha-
geal SCC patients, suggesting its potential utility as an oesophageal
SCC detection marker for early onset of oesophageal SCC
development.
Having a FH of oesophageal cancer is one of the significant risk
factors for oesophageal SCC. This is also associated with several
clinical features, including higher prevalence rate of double
primary oesophageal SCC and having a worse prognosis than for
sporadic cases (Wen et al, 2009). Socioeconomic status, living
environment, and dietary habits are associated with familial
clustering of EC (De Groot, 2006). Not much is known regarding
the molecular alterations underlying familial oesophageal SCC,
although our recent genome-wide association study has now
identified susceptibility loci at PLCE1 and C20orf53 (Wang et al,
2010). Downregulation of TGF-b signalling (SMAD1) is reported in
tumour tissues of familial oesophageal SCC patients (Chattopad-
hyay et al, 2009). In China, allelic loss of chromosome 13 regions
was significantly found in patients with a positive FH of
oesophageal SCC compared with negative history (Hu et al,
2003). Oesophageal SCC family members show aberrant methyla-
tion on the promoter of p16 (Abbaszadegan et al, 2005). Here, we
document one more molecular alteration associated with this risk
factor. Decreased expression of DEC1 in tissues of oesophageal
SCC patients is significantly correlated with oesophageal SCC FH
status. The statistically significant lower DEC1 staining observed in
the FHþ hyperplasia vs that in the FH– hyperplasia suggests that
loss or reduced DEC1 expression appears to be an early event in
ESCC development in FHþ patients. Further study with larger
sample sizes is needed for substantiation of the current result. The
mechanistic explanation for this observation warrants further
investigation.
Three independent in silico protein analysis programs, ROSETTA
(http://boinc.bakerlab.org/rosetta/), SMART (http://smart.embl-
heidelberg.de/), and DisEMBL 1.5 (http://dis.embl.de/) identified
intrinsic disorder regions at around 10 residues at the N-terminus
and the C-terminus of DEC1. Intrinsic disorder regions frequently
act as sites of posttranslational modifications and are common
among cell signalling and cancer-associated proteins (Iakoucheva
et al, 2002). Its localisation in the cytoplasm and nuclear
compartments, as observed in immunostaining and subcellular
fractionation experiments, is consistent with its possible role in
cellular signalling and signal transduction.
Not only does the Golgi apparatus have a well-characterised
function in the secretory pathway, but it also controls centrosome
organisation, cell cycle progression, cell polarisation, and cell
migration. The Golgi re-orientation towards invadopodia is
important for directing cell invasion (Buccione et al, 2009).
Interestingly, the DEC1 antibody detects vesicular DEC1 located at
the Golgi and ER–Golgi intermediate compartments. DEC1
colocalises with GM130, a cis-Golgi protein regulating cell
migration (Preisinger et al, 2004). Indeed, stable expression of
DEC1 in oesophageal SCC cell lines upregulates dual-specificity
phosphatase 6 (Leung et al, 2008), a tumour- and cell invasion-
suppressor gene that is associated with patient survival in
oesophageal SCC (Wong et al, 2011). Further investigations are
required to elucidate the molecular mechanism of DEC1 in
oesophageal SCC.
Taken together, this TMA study reveals the important clinical
relevance of DEC1 in lymph node metastatic oesophageal SCC, in
early onset oesophageal SCC and familial oesophageal SCC
development, further solidifying the crucial role of DEC1 in
oesophageal SCC malignancies. This finding adds a novel
candidate to the current repertoire of oesophageal SCC diagnostic
markers. Moreover, these studies on the subcellular localisation of
DEC1 show that it localises to both the cytoplasm and nucleus.
Cytoplasmic vesicular DEC1 proteins appear to localise to the
Golgi and ER–Golgi intermediate compartment, providing a
pivotal clue for further study into the detailed molecular
mechanism of DEC1 in oesophageal SCC development.
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